November 29, 2016 - By Michael Collier
Scotia Capital have a $5.00 target price on the stock. The target price means a potential upside of 100.80% from ProMetic Life Sciences (TSE:PLI)‘s previous close. This rating was disclosed in analysts note on Tuesday morning.
Out of 6 analysts covering ProMetic Life Sciences Inc. (TSE:PLI), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $6.70 is the highest target while $3 is the lowest. The $5.14 average target is 108.94% above today’s ($2.46) stock price. ProMetic Life Sciences Inc. has been the topic of 24 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Tuesday, December 15 by RBC Capital Markets. As per Tuesday, November 22, the company rating was maintained by Scotia Capital. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, November 16. The stock of ProMetic Life Sciences Inc. (TSE:PLI) earned “Outperform” rating by Scotia Capital on Wednesday, November 16. As per Wednesday, June 15, the company rating was maintained by RBC Capital Markets. RBC Capital Markets maintained the stock with “Outperform” rating in Monday, October 5 report. The rating was maintained by Scotia Capital with “Outperform” on Thursday, October 27. The company was maintained on Thursday, August 11 by Scotia Capital. Paradigm Research reinitiated the stock with “Buy” rating in Monday, September 28 report. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, August 25.
The stock increased 9.82% or $0.22 on November 29, hitting $2.46. About 4.17 million shares traded hands or 84.51% up from the average. ProMetic Life Sciences Inc. (TSE:PLI) has declined 34.50% since April 25, 2016 and is downtrending. It has underperformed by 39.76% the S&P500.
ProMetic Life Sciences Inc. is a Canada biopharmaceutical company. The company has a market cap of $1.44 billion. The Firm has two divisions: Small Molecule Therapeutics and Protein Technology. It currently has negative earnings. The Firm offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Another recent and important ProMetic Life Sciences Inc. (TSE:PLI) news was published by Marketwatch.com which published an article titled: “Thomvest Asset Management Inc. reports Prometic Life Sciences Inc. share …” on March 11, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.